Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 18/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 15/20 | 0.49 |
| ▸ | FGFR4 | P22455 | 15/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 15/20 | 0.49 |
| ▸ | KDR | P35968 | 11/20 | 0.49 |
| ▸ | FLT1 | P17948 | 10/20 | 0.49 |
| ▸ | FLT4 | P35916 | 10/20 | 0.49 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CSK | P41240 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 3/20 | 0.37 |
| ▸ | MAP3K8 | P41279 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20258228 | 0.94 | FGFR1 (0.56) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL15047131 | 0.86 | FGFR1 (0.67) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL15047125 | 0.79 | FGFR1 (0.66) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL20016460 | 0.78 | FGFR1 (0.41) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL24490289 | 0.77 | FGFR1 (0.50) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL16383020 | 0.76 | FGFR1 (0.61) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL15047134 | 0.74 | FGFR1 (0.64) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL15047149 | 0.74 | FGFR1 (0.71) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL16383019 | 0.74 | FGFR1 (0.68) | FGFR1FGFR2FGFR4FGFR3KDR | |
| SCHEMBL15047129 | 0.73 | FGFR1 (0.61) | FGFR1FGFR2FGFR4FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161327-A1 | ANTAGONIST OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR USE IN THE TREATMENT OR THE PREVENTION OF SKELETAL DISORDERS LINKED WITH ABNORMAL ACTIVATION OF FGFR3 | ASSISTANCE PUBLIQUE HOPITAUX DE PARIS (FR) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161327-A1 | ANTAGONIST OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR USE IN THE TREATMENT OR THE PREVENTION OF SKELETAL DISORDERS LINKED WITH ABNORMAL ACTIVATION OF FGFR3 | FGFR3, FGFR1, FGFR2 | FGFR1 2/4885FGFR2 3/4885FGFR4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.